Gemcitabine and carboplatin in metastatic nonsmall cell lung cancer: Experience from a tertiary cancer center in South India

AbstractMaintaining appropriate dose intensity is important not only in the curative setting but also in treatment with palliative intent. We evaluated the outcome of advanced non small cell lung cancer treated with doublet platinum based chemotherapy. Outcome was compared between patients treated by medical oncologists at a tertiary cancer center and those treated by non medical oncologists in the community. The dose intensity, overall response rate and overall survival was significantly better when patients were treated by trained qualified and experienced medical oncologists. Hence, even in the palliative setting, cancer directed systemic therapy will yield maximum benefit for the patients when treated by medical oncologists.

Download Full-text

Metastatic nonsmall cell lung cancer in South India: A regional demographic study

Indian Journal of Cancer ◽

10.4103/0019-509x.219566 ◽

2017 ◽

Vol 54 (1) ◽

pp. 267

Author(s):

MP Kamath ◽

KC Lakshmaiah ◽

KG Babu ◽

U Amirtham ◽

D Loknatha ◽

...

Keyword(s):

Lung Cancer ◽

Cell Lung Cancer ◽

South India ◽

Nonsmall Cell Lung Cancer ◽

Demographic Study

Download Full-text

Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center

Indian Journal of Cancer ◽

10.4103/ijc.ijc_469_17 ◽

2018 ◽

Vol 55 (2) ◽

pp. 125

Author(s):

RajKumar Shrimali ◽

Chandran Nallathambi ◽

Animesh Saha ◽

Avipsa Das ◽

Sriram Prasath ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Locally Advanced ◽

Small Cell ◽

Cancer Center ◽

Radical Radiotherapy ◽

Small Cell Lung ◽

Patient Profile ◽

Tertiary Cancer Center

Download Full-text

Referral Characteristics of Palliative Care Service in Patients With Advanced Non-Small Cell Lung Cancer in a Tertiary Cancer Center

American Journal of Hospice and Palliative Medicine® ◽

10.1177/1049909119867281 ◽

2019 ◽

Vol 37 (4) ◽

pp. 266-271

Author(s):

Xiaoli Gu ◽

Menglei Chen ◽

Minghui Liu ◽

Zhe Zhang ◽

Weiwei Zhao ◽

...

Keyword(s):

Lung Cancer ◽

Palliative Care ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Advanced Nsclc ◽

Small Cell ◽

Cancer Center ◽

Small Cell Lung ◽

The Mean ◽

Tertiary Cancer Center

Background: The American Society of Clinical Oncology recently recommends patients with metastatic non-small cell lung cancer (NSCLC) should be offered palliative care services earlier. We sought to investigate the timing of palliative care referral of Chinese patients with NSCLC in our center. Method: Retrospective medical data including demographic characteristics and referral information were collected for analysis. Overall survival (OS) was calculated as the time since cancer diagnosis till patient’s death. The time interval from palliative care (PC) referral to a patient’s death (PC-D) was calculated. The PC-D/OS ratio was calculated to illustrate the comparison of the duration of PC in the overall length of disease. Results: The mean age of 155 patients with advanced NSCLC was 62.83 years. Before referral to PC, 128 patients received anticancer treatment including surgeon (46.5%). Sixty-three (40.6%) patients died in palliative care unit. The median OS of 144 patients with end cutoff was 19 months (mean = 31.49, 95% confidence interval [CI] = 25.86-37.12). The median PC-D was 41 days (mean = 73.84, 95% CI = 60.37-87.40). The mean interval of PC-D/OS of 144 patients with definitely death time was 0.22 (SD: 0.27, 95% CI: 0.17-0.26). The median interval was 0.089. More than half of patients (n = 75, 51.8%) underwent PC less than 1% time (PC-D/OS < 0.1) of their whole disease course. Patients who were indigenous to Shanghai ( P = .013) and who had brain metastasis ( P = .072) had the potential longer PC-D/OS ratio. A high proportion of patients reported loss of appetite (92.8%) and fatigue (91.4%) at the initial of referral to PC. Conclusion: This retrospective study, in a population of patients with advanced NSCLC, gave detailed information about PC services in a tertiary cancer center.

Download Full-text

Long‐term outcomes of high‐dose (74 GyE ) proton beam therapy with concurrent chemotherapy for stage III nonsmall‐cell lung cancer

Thoracic Cancer ◽

10.1111/1759-7714.13896 ◽

2021 ◽

Author(s):

Kayoko Ohnishi ◽

Hitoshi Ishikawa ◽

Kensuke Nakazawa ◽

Toshihiro Shiozawa ◽

Yutaro Mori ◽

...

Keyword(s):

Lung Cancer ◽

Proton Beam ◽

Cell Lung Cancer ◽

Nonsmall Cell Lung Cancer ◽

Proton Beam Therapy ◽

Concurrent Chemotherapy ◽

Stage Iii ◽

High Dose ◽

Long Term Outcomes

Download Full-text

Complete metabolic response in patients with advanced nonsmall cell lung cancer with prolonged response to immune checkpoint inhibitor therapy

Journal for ImmunoTherapy of Cancer ◽

10.1136/jitc-2020-002262 ◽

2021 ◽

Vol 9 (3) ◽

pp. e002262

Author(s):

Justin Ferdinandus ◽

Martin Metzenmacher ◽

Lukas Kessler ◽

Lale Umutlu ◽

Clemens Aigner ◽

...

Keyword(s):

Lung Cancer ◽

Cell Lung Cancer ◽

Metabolic Response ◽

Standard Of Care ◽

Nonsmall Cell Lung Cancer ◽

Published Data ◽

Complete Metabolic Response ◽

Positron Emission ◽

Checkpoint Inhibitor Therapy

IntroductionImmunotherapy is the new standard of care in advanced nonsmall cell lung cancer (NSCLC). Recently published data show that treatment discontinuation after 12 months of nivolumab treatment is associated with shorter survival. Therefore, the ideal duration of immunotherapy remains unclear, and finding markers of beneficial outcomes is of great importance. Here, we determine the proportion of complete metabolic responses (CMR) in patients who have not progressed after 24 months of immunotherapy.MethodsThis is a retrospective analysis of 45 patients with positron emission tomography using 2-[18F]fluoro-2-deoxy-D-glucose imaging for assessment of residual metabolic activity after at least 24 months. CMR was defined as uptake in tumor lesions below background levels, using mediastinum as a reference. ResultsOut of 45 patients, 29 patients had a CMR (64%). CMR was observed more frequently in non-first-line patients. Patients with CMR were younger (median 65.7 vs 75.5, p=0.03). Fourteen patients with CMR have discontinued therapy and have not progressed until time of analysis; however, median follow-up was only 5.6 (range 0.8–17.0) months.ConclusionAfter a minimum of 24 months of palliative immunotherapy for NSCLC, CMR occurred in almost two thirds of patients. Potentially, achievement of CMR might identify patients, for whom palliative immunotherapy may be safely discontinued.

Download Full-text